Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
14 Août 2024 - 2:00PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Bellevue Life
Sciences Acquisition Corp.
(Name of Issuer)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
079174108
(CUSIP Number)
June 30, 2024
(Date of Event which Requires Filing of this Statement)
Check the appropriate box to
designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)
| * |
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form
with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. |
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
|
|
|
|
|
|
|
| 1. |
|
NAMES OF REPORTING PERSONS
Bellevue Global Life Science Investors, LLC |
| 2. |
|
CHECK THE APPROPRIATE BOX IF A
MEMBER OF A GROUP* (see instructions) (a) ☐ (b) ☐
|
| 3. |
|
SEC USE ONLY
|
| 4. |
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Delaware |
|
|
|
|
|
|
|
| NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
|
5. |
|
SOLE VOTING POWER
1,355,000 (1) |
| |
6. |
|
SHARED VOTING POWER
|
| |
7. |
|
SOLE DISPOSITIVE POWER
1,355,000 (1) |
| |
8. |
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
| 9. |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,355,000 |
| 10. |
|
CHECK IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES* (see instructions) ☐ |
| 11. |
|
PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW 9 33.5% (2) |
| 12. |
|
TYPE OF REPORTING PERSON* (see
instructions) OO |
| (1) |
Represents shares of common stock held by Bellevue Global Life Sciences Investors, LLC, the sponsor of the
Issuer (the “Sponsor”), including 34,500 shares held in escrow until the consummation of an initial business combination for the benefit of Chardan Capital Markets, LLC, the representative of the underwriters of the initial public
offering. The general partner of the Sponsor is Bellevue Capital Management LLC (“Bellevue Capital”). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor.
|
| (2) |
Based on a total of 4,041,221 shares outstanding of the Issuer as set forth in the Issuer’s Current Report
on Form 8-K filed with the Securities and Exchange Commission on May 14, 2024. |
2
|
|
|
|
|
|
|
| 1. |
|
NAMES OF REPORTING PERSONS
BCM Europe AG |
| 2. |
|
CHECK THE APPROPRIATE BOX IF A
MEMBER OF A GROUP* (see instructions) (a) ☐ (b) ☐
|
| 3. |
|
SEC USE ONLY
|
| 4. |
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Switzerland |
|
|
|
|
|
|
|
| NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
|
5. |
|
SOLE VOTING POWER
680,000 (1) |
| |
6. |
|
SHARED VOTING POWER
|
| |
7. |
|
SOLE DISPOSITIVE POWER
680,000 (1) |
| |
8. |
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
| 9. |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
680,000 |
| 10. |
|
CHECK IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES* (see instructions) ☐ |
| 11. |
|
PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW 9 16.8% (2) |
| 12. |
|
TYPE OF REPORTING PERSON* (see
instructions) OO |
| (1) |
Represents shares from 310,000 private placement units and 370,000 shares of common stock eligible to be
converted by BCM Europe AG (“BCME”) as a result of the promissory note between the Sponsor and BCME. The promissory note between the Sponsor and BCME is convertible at the election of either the Sponsor or BCME on or after the commencement
of the Issuer’s initial public offering into (i) 310,000 private placement units held by the Sponsor, (ii) 370,000 founder shares held by the Sponsor, and (iii) 60,000 warrants held by the Sponsor. BCME is a wholly-owned subsidiary of Bellevue
Capital. Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. |
| (2) |
Based on a total of 4,041,221 shares outstanding of the Issuer as set forth in the Issuer’s Current Report
on Form 8-K filed with the Securities and Exchange Commission on May 14, 2024. |
3
|
|
|
|
|
|
|
| 1. |
|
NAMES OF REPORTING PERSONS
Bellevue Capital Management LLC |
| 2. |
|
CHECK THE APPROPRIATE BOX IF A
MEMBER OF A GROUP* (see instructions) (a) ☐ (b) ☐
|
| 3. |
|
SEC USE ONLY
|
| 4. |
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Washington |
|
|
|
|
|
|
|
| NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
|
5. |
|
SOLE VOTING POWER
2,035,000 (1) |
| |
6. |
|
SHARED VOTING POWER
|
| |
7. |
|
SOLE DISPOSITIVE POWER
2,035,000 (1) |
| |
8. |
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
| 9. |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,035,000 |
| 10. |
|
CHECK IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES* (see instructions) ☐ |
| 11. |
|
PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW 9 50.4% (2) |
| 12. |
|
TYPE OF REPORTING PERSON* (see
instructions) OO |
| (1) |
Represents (1) shares of common stock held by the Sponsor and (2) the shares eligible for conversion
by BCME. The general partner of the Sponsor is Bellevue Capital and BCME is a wholly-owned subsidiary of Bellevue Capital. Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the
Sponsor. |
| (2) |
Based on a total of 4,041,221 shares outstanding of the Issuer as set forth in the Issuer’s Current Report
on Form 8-K filed with the Securities and Exchange Commission on May 14, 2024. |
4
|
|
|
|
|
|
|
| 1. |
|
NAMES OF REPORTING PERSONS
Kuk Hyoun Hwang |
| 2. |
|
CHECK THE APPROPRIATE BOX IF A
MEMBER OF A GROUP* (see instructions) (a) ☐ (b) ☐
|
| 3. |
|
SEC USE ONLY
|
| 4. |
|
CITIZENSHIP OR PLACE OF
ORGANIZATION
Korea |
|
|
|
|
|
|
|
| NUMBER OF
SHARES BENEFICIALLY
OWNED BY EACH
REPORTING PERSON
WITH |
|
5. |
|
SOLE VOTING POWER
2,035,000 (1) |
| |
6. |
|
SHARED VOTING POWER
|
| |
7. |
|
SOLE DISPOSITIVE POWER
2,035,000 (1) |
| |
8. |
|
SHARED DISPOSITIVE POWER
|
|
|
|
|
|
|
|
| 9. |
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,035,000 |
| 10. |
|
CHECK IF THE AGGREGATE AMOUNT
IN ROW (9) EXCLUDES CERTAIN SHARES* (see instructions) ☐ |
| 11. |
|
PERCENT OF CLASS REPRESENTED BY
AMOUNT IN ROW 9 50.4% (2) |
| 12. |
|
TYPE OF REPORTING PERSON* (see
instructions) IN |
| (1) |
Represents (1) shares of common stock held by the Sponsor and (2) the shares eligible for conversion
by BCME. The general partner of the Sponsor is Bellevue Capital and BCME is a wholly-owned subsidiary of Bellevue Capital. Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the
Sponsor. |
| (2) |
Based on a total of 4,041,221 shares outstanding of the Issuer as set forth in the Issuer’s Current Report
on Form 8-K filed with the Securities and Exchange Commission on May 14, 2024. |
5
EXPLANATORY NOTE
This Amendment No. 1 (this “Amendment No. 1”) amends and supplements the statement on Schedule 13G (the “Original
Schedule 13G”) filed on February 8, 2024 with the U.S. Securities and Exchange Commission (the “SEC”) on behalf of Bellevue Global Life Science Investors, LLC (the “Sponsor”), Bellevue Capital Management LLC
(“Bellevue Capital”) and Kuk Hyoun Hwang, with respect to the Common Stock, par value $0.0001 per share (“Common Stock”), of Bellevue Life Sciences Acquisition Corp., a Delaware corporation (the “Issuer”) (the Original
Schedule 13G, as amended by this Amendment No. 1, the “Schedule 13G”). Only those items that are amended or supplemented are reported herein. All capitalized terms used in this Amendment No. 1 and not otherwise defined herein
have the meanings ascribed to such terms in the Schedule 13G.
Item 2 of the Schedule 13G is hereby amended and restated in its entirety as follows:
| |
(a) |
Name of Person Filing: |
| |
(1) |
Bellevue Global Life Science Investors, LLC (the “Sponsor”) |
| |
(2) |
BCM Europe AG (“BCME”) |
| |
(3) |
Bellevue Capital Management LLC (“Bellevue Capital”) |
| |
(b) |
Address of Principal Business Office, or if None, Residence: |
The address for these entities and this individual is:
c/o Bellevue Life Sciences Acquisition Corp.
10900 NE 4th Street
Suite 2300
Bellevue, WA 98004
| |
(3) |
Bellevue Capital – Washington |
| |
(4) |
Kuk Hyoun Hwang – Republic of Korea |
| |
(d) |
Title of Class of Securities: Common Stock, par value $0.0001 per share |
| |
(e) |
CUSIP Number: 079174108 |
Item 4 of the Schedule 13G is hereby amended and restated in its entirety as follows:
The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page of this Amendment No. 1 for each Reporting Person
and is incorporated herein by reference for each Reporting Person.
6
EXHIBIT INDEX
|
|
|
| Exhibit Number |
|
Description |
|
|
| 99.1 |
|
Joint Filing Agreement among the Reporting Persons regarding filing of Schedule 13G, dated August 13, 2024. |
7
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true,
complete and correct.
|
|
|
|
|
|
|
|
|
|
|
BELLEVUE GLOBAL LIFE SCIENCE INVESTORS, LLC |
|
|
|
| August 14, 2024 |
|
|
|
By: Bellevue Capital Management LLC, Its Manager |
|
|
|
|
|
|
|
|
By: |
|
/s/ Kuk Hyoun Hwang |
|
|
|
|
|
|
Kuk Hyoun Hwang, Managing Member of Bellevue Capital Management LLC |
|
|
|
|
|
|
|
BCM EUROPE AG |
|
|
|
|
| August 14, 2024 |
|
|
|
By: |
|
/s/ Kuk Hyoun Hwang |
|
|
|
|
|
|
Kuk Hyoun Hwang, Managing Member |
|
|
|
|
|
|
|
BELLEVUE CAPITAL MANAGEMENT LLC |
|
|
|
|
| August 14, 2024 |
|
|
|
By: |
|
/s/ Kuk Hyoun Hwang |
|
|
|
|
|
|
Kuk Hyoun Hwang, Managing Member |
|
|
|
|
|
|
|
KUK HYOUN HWANG |
|
|
|
| August 14, 2024 |
|
|
|
/s/ Kuk Hyoun Hwang |
|
|
|
|
Kuk Hyoun Hwang |
EXHIBIT 99.1
CUSIP No. 079174108
JOINT FILING STATEMENT
PURSUANT TO RULE 13D-1(K)(1)
The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common
Stock of Bellevue Life Sciences Acquisition Corp. together with any or all amendments thereto, when and if required. The parties hereto further consent and agree to file this Joint Filing Statement pursuant to
Rule13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G.
This
Joint Filing Statement may be terminated by any of the undersigned upon written notice or such lesser period of notice as the undersigned may mutually agree.
Dated: August 13, 2024
|
|
|
|
|
|
|
|
|
|
|
BELLEVUE GLOBAL LIFE SCIENCE INVESTORS, LLC |
|
|
|
|
|
|
|
BY: BELLEVUE CAPITAL MANAGEMENT LLC, ITS MANAGER |
|
|
|
|
|
|
|
|
By: |
|
/s/ Kuk Hyoun Hwang |
|
|
|
|
|
|
Kuk Hyoun Hwang, Managing Member of Bellevue Capital Management LLC |
|
|
|
|
|
|
|
BCM EUROPE AG |
|
|
|
|
|
|
|
|
By: |
|
/s/ Kuk Hyoun Hwang |
|
|
|
|
|
|
Kuk Hyoun Hwang, Managing Member |
|
|
|
|
|
|
|
BELLEVUE CAPITAL MANAGEMENT LLC |
|
|
|
|
|
|
|
|
By: |
|
/s/ Kuk Hyoun Hwang |
|
|
|
|
|
|
Kuk Hyoun Hwang, Managing Member |
|
|
|
|
|
|
|
KUK HYOUN HWANG |
|
|
|
|
|
|
|
/s/ Kuk Hyoun Hwang |
|
|
|
|
Kuk Hyoun Hwang |
Bellevue Life Sciences A... (NASDAQ:BLACU)
Graphique Historique de l'Action
De Jan 2025 à Fév 2025
Bellevue Life Sciences A... (NASDAQ:BLACU)
Graphique Historique de l'Action
De Fév 2024 à Fév 2025
